Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $28.76 in the prior trading day, Tandem Diabetes Care Inc (NASDAQ: TNDM) closed at $27.87, down -3.09%. In other words, the price has decreased by -$3.09 from its previous closing price. On the day, 1.34 million shares were traded. TNDM stock price reached its highest trading level at $28.595 during the session, while it also had its lowest trading level at $27.66.
Ratios:
Our goal is to gain a better understanding of TNDM by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.32 and its Current Ratio is at 2.90. In the meantime, Its Debt-to-Equity ratio is 2.00 whereas as Long-Term Debt/Eq ratio is at 1.76.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Bernstein on November 06, 2024, initiated with a Outperform rating and assigned the stock a target price of $42.
On October 04, 2024, Goldman started tracking the stock assigning a Neutral rating and target price of $46.
On October 02, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $65.RBC Capital Mkts initiated its Outperform rating on October 02, 2024, with a $65 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 15 ’24 when Novara Mark David bought 532 shares for $23.24 per share. The transaction valued at 12,364 led to the insider holds 532 shares of the business.
Allen Dick sold 5,000 shares of TNDM for $258,400 on May 30 ’24. The Director now owns 0 shares after completing the transaction at $51.68 per share. On Nov 27 ’23, another insider, Allen Dick, who serves as the Director of the company, bought 5,000 shares for $18.96 each. As a result, the insider paid 94,778 and bolstered with 19,962 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNDM now has a Market Capitalization of 1830404096 and an Enterprise Value of 1891498112. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.14 while its Price-to-Book (P/B) ratio in mrq is 7.70. Its current Enterprise Value per Revenue stands at 2.214 whereas that against EBITDA is -14.472.
Stock Price History:
Over the past 52 weeks, TNDM has reached a high of $53.69, while it has fallen to a 52-week low of $17.33. The 50-Day Moving Average of the stock is -24.53%, while the 200-Day Moving Average is calculated to be -26.76%.
Shares Statistics:
The stock has traded on average 1.31M shares per day over the past 3-months and 2106810 shares per day over the last 10 days, according to various share statistics. A total of 65.55M shares are outstanding, with a floating share count of 65.16M. Insiders hold about 0.79% of the company’s shares, while institutions hold 112.72% stake in the company. Shares short for TNDM as of 1730332800 were 8392280 with a Short Ratio of 6.41, compared to 1727654400 on 10073142. Therefore, it implies a Short% of Shares Outstanding of 8392280 and a Short% of Float of 19.790001.
Earnings Estimates
Tandem Diabetes Care Inc (TNDM) is presently subject to a detailed evaluation by 18.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.19 and low estimates of -$0.66.
Analysts are recommending an EPS of between -$1.52 and -$1.86 for the fiscal current year, implying an average EPS of -$1.72. EPS for the following year is -$1.2, with 20.0 analysts recommending between -$0.72 and -$1.51.
Revenue Estimates
18 analysts predict $251.5M in revenue for the current quarter. It ranges from a high estimate of $280.5M to a low estimate of $244.8M. As of the current estimate, Tandem Diabetes Care Inc’s year-ago sales were $196.8MFor the next quarter, 18 analysts are estimating revenue of $221.9M. There is a high estimate of $234M for the next quarter, whereas the lowest estimate is $213.88M.
A total of 21 analysts have provided revenue estimates for TNDM’s current fiscal year. The highest revenue estimate was $938.1M, while the lowest revenue estimate was $874.45M, resulting in an average revenue estimate of $907.47M. In the same quarter a year ago, actual revenue was $747.72MBased on 21 analysts’ estimates, the company’s revenue will be $1.01B in the next fiscal year. The high estimate is $1.04B and the low estimate is $984.2M.
